公开(公告)号：US20240385201A1

公开(公告)日：2024-11-21

申请号：US18669809

申请日：2024-05-21

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo LAAKSONEN ,  Kim EKROOS ,  Reini HURME ,  Riikka KATAINEN

IPC: G01N33/92 ,  A61K31/366 ,  A61K31/397

Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

公开(公告)号：US10261101B2

公开(公告)日：2019-04-16

申请号：US15803252

申请日：2017-11-03

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

IPC: G01N33/92

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

公开(公告)号：US09459264B2

公开(公告)日：2016-10-04

申请号：US14712422

申请日：2015-05-14

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riika Katainen

IPC: G01N33/92

CPC classification number: G01N33/92 ,  A61K31/366 ,  A61K31/397 ,  G01N2405/04 ,  G01N2570/00 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

公开(公告)号：US09046538B2

公开(公告)日：2015-06-02

申请号：US13695766

申请日：2011-05-05

Applicant: Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Janis ,  Riika Katainen ,  Kirill Tarasov

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Janis ,  Riika Katainen ,  Kirill Tarasov

IPC: G01N33/92

CPC classification number: G01N33/92 ,  A61K31/366 ,  A61K31/397 ,  G01N2405/04 ,  G01N2570/00 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来诊断和/或预测动脉粥样硬化或CVD的方法及其用途，并且鉴定了特异性的特异性脂质标记物 并且在检测和预测动脉粥样硬化和CVD时比目前使用的临床标志物敏感。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗动脉粥样硬化或CVD的用途。 本发明还涉及包含脂质和/或其抗体的试剂盒，用于预测和/或诊断动脉粥样硬化或CVD。

公开(公告)号：US09841431B2

公开(公告)日：2017-12-12

申请号：US14875087

申请日：2015-10-05

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2405/04 ,  G01N2405/06 ,  G01N2570/00 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

公开(公告)号：US09541565B2

公开(公告)日：2017-01-10

申请号：US13332773

申请日：2011-12-21

Applicant: Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Jänis ,  Riikka Katainen ,  Kirill Tarasov

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Jänis ,  Riikka Katainen ,  Kirill Tarasov

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2570/00 ,  G01N2800/10 ,  G01N2800/2871 ,  G01N2800/325

Abstract: The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.

Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质 - 脂质浓度比例来预测他汀类药物诱发的肌肉毒性或其并发症如肌痛，肌病和横纹肌溶解症的方法及其用途，并比较它们 控制。 该方法已经鉴定了在检测这些他汀类药物诱导的肌肉毒性中比目前使用的临床标记物更具特异性和更灵敏的脂质标记物。 还提供了针对所述脂质的抗体及其用于预测，诊断他汀类药物诱导的肌肉毒性的用途。 本发明还涉及包含脂质和/或其抗体的试剂盒，用于预测和/或诊断他汀类药物诱导的肌肉毒性。

公开(公告)号：US09347960B2

公开(公告)日：2016-05-24

申请号：US14677595

申请日：2015-04-02

Applicant: ZORA BIOSCIENCES, OY

Inventor： Reijo Laaksonen

IPC: G01N33/92 ,  C07B59/00

CPC classification number: G01N33/92 ,  A61K31/164 ,  C07B59/001 ,  G01N2405/08 ,  G01N2458/15 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.

Abstract translation: 本发明尤其提供了通过测定A组中至少一种神经酰胺和至少一种B组神经酰胺的浓度来预测CV并发症如AMI，ACS，中风和CV死亡的方法及其用途。 生物样品，并将这些浓度与对照组比较。 发现降低浓度的至少一种A组神经酰胺和增加浓度的至少一种B组神经酰胺表明受试者具有发展一种或多种CV并发症的风险增加。 还提供了新确定的神经酰胺分子的子集，其标记的版本，以及包含其的用于预测和/或诊断CV并发症的试剂盒和组合物。

公开(公告)号：US09052328B2

公开(公告)日：2015-06-09

申请号：US14356594

申请日：2012-11-07

Applicant: Zora Biosciences OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Jänis ,  Riikka Katainen ,  Kirill Tarasov

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2570/00 ,  G01N2800/042 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/70

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。

公开(公告)号：US20140031332A1

公开(公告)日：2014-01-30

申请号：US14110219

申请日：2011-04-08

Applicant: Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Janis ,  Riikka Katainen ,  Kirill Tarasov

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Janis ,  Riikka Katainen ,  Kirill Tarasov

IPC: G01N33/92

CPC classification number: G01N33/92 ,  A61B5/7275 ,  G01N30/7233 ,  G01N2030/8813 ,  G01N2800/10 ,  G01N2800/325 ,  G01N2800/52 ,  G06F19/00

Abstract: The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.

Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照相比较来预测他汀类药物诱发的肌肉毒性或其并发症如肌痛，肌病和横纹肌溶解症的方法及其用途 。 该方法已经鉴定了在检测这些他汀类药物诱导的肌肉毒性中比目前使用的临床标记物更具特异性和更灵敏的脂质标记物。 还提供了针对所述脂质的抗体及其用于预测，诊断他汀类药物诱导的肌肉毒性的用途。 本发明还涉及包含脂质和/或其抗体的试剂盒，用于预测和/或诊断他汀类药物诱导的肌肉毒性。

公开(公告)号：US20130216560A1

公开(公告)日：2013-08-22

申请号：US13805319

申请日：2011-06-20

Applicant: Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Jänis ,  Riikka Katainen ,  Kirill Tarasov

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Jänis ,  Riikka Katainen ,  Kirill Tarasov

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2405/04 ,  G01N2405/06 ,  G01N2570/00 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。